After receiving anti-programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) treatment, adenocarcinoma patients positive for EGFR mutant show poorer responses than those with the wild-type (2). The gene discussed is EGFR; the disease is adenocarcinoma.